newsfilter
← Latest News
Business Wire·

AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your Rights

  • Investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) have until November 30, 2026, to request appointment as lead plaintiff in a securities fraud class action.
  • The lawsuit covers the class period from November 26, 2025, through August 28, 2026.
  • The complaint alleges Anavex made false statements & failed to disclose inadequate internal controls & regulatory challenges stemming from misconduct by former CEO Christopher Missling.
  • On May 6, 2026, Anavex disclosed the immediate termination of CEO Missling due to policy violations, causing shares to drop 0.59% to $3.34.
  • On May 11, 2026, Anavex filed for a late Form 10-Q submission for the March 31, 2026 quarter, citing the CEO termination review, leading to a 5.55% share price decline to $3.06.
  • On August 28, 2026, Anavex filed an amended 10-K report admitting ineffective disclosure controls & a material weakness in financial reporting, resulting in a 6.35% share price drop to $2.80.
  • The amended report stated the former CEO lacked transparency with the board & disincentivized regulatory compliance efforts.
  • Kirby McInerney LLP is handling the case & offers free consultations to investors who suffered losses via email or a contact form.